ProfileGDS5678 / 1437462_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 85% 76% 77% 79% 79% 83% 83% 78% 83% 83% 82% 82% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6944881
GSM967853U87-EV human glioblastoma xenograft - Control 26.3600285
GSM967854U87-EV human glioblastoma xenograft - Control 35.1129476
GSM967855U87-EV human glioblastoma xenograft - Control 45.4052377
GSM967856U87-EV human glioblastoma xenograft - Control 55.6244179
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3890879
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9790383
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0047683
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.329478
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1027583
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0490983
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9530682
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.865582
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2057484